# Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

> **NCT00973076** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 19 (actual)

## Conditions studied

- Cancer
- Solid Tumors
- Advanced Solid Malignancies

## Interventions

- **DRUG:** AZD8055

## Key facts

- **NCT ID:** NCT00973076
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2011-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00973076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00973076, "Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00973076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*